Please ensure Javascript is enabled for purposes of website accessibility

Why Acadia Pharmaceuticals Is Crashing Today

By Brian Feroldi – Apr 9, 2018 at 11:42AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Traders flee after a troublesome news report emerged related to the company's only drug, Nuplazid. Here's what investors need to know.

What happened

After CNN published a news report that highlights a growing number of patient deaths and adverse events that may be related to the use of the drug Nuplazid, shares of Acadia Pharmaceuticals (ACAD 2.76%), a commercial-stage drugmaker focused on diseases of the central nervous system, fell 22% as of 10:45 a.m. EST Monday.

So what

Every shareholder of Acadia should read the entire CNN article, but here is a summary of the key points:

  • More than 1,000 patients have continued to experience hallucinations while taking Nuplazid.
  • More than 700 patients taking Nuplazid have died since the drug was launched. Nuplazid was listed as "suspect" in at least 500 reported cases.
  • Some physicians and medical experts told CNN that they were worried Nuplazid was "approved too quickly, based on too little evidence that it was safe or effective." 

Understandably, this news isn't sitting well with traders, which is why shares are plunging today.

A person wearing a suit sitting next to a laptop with their hands on their head and a worried look on their face.

Image source: Getty Images.

Acadia's management team responded to this news report with a few key points of its own:

  • Patients who develop Parkinson's disease psychosis (PDP) tend to be older and are chronically ill. They also tend to be on many different medications and show numerous medical comorbidities. These factors are associated with a high risk of morbidity and mortality.
  • Acadia regularly monitors the mortality risk for Nuplazid and reports data to the FDA each quarter. Since launch, the overall mortality rate of patients who use Nuplazid is 12.4 deaths per 100 patient years. That's less than half of the 28.2 deaths per 100 patient years that is observed in the PDP population in general.
  • The FDA has not identified a specific safety issue that is not already described in Nuplazid's labeling.
  • Acadia has conducted two studies that involve more than 300 patients with Alzheimer's disease since the drug's approval in 2016. In these studies, there was no difference in the number of deaths reported among patients who use Nuplazid or a placebo.

Now what

It is hard to know what to make of this report. On one hand, this article raises some real concerns and it is difficult to read that so many patients have died while using Nuplazid. On the other hand, it is important to remember that patients who develop PDP are extremely sick and have a high risk of mortality whether or not and they choose to use Nuplazid.

Investors will have to decide for themselves whether or not they feel comfortable continuing to own shares. Either way, I'd advise them to monitor this story as it continues to develop.

Brian Feroldi has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Acadia Pharmaceuticals Stock Quote
Acadia Pharmaceuticals
ACAD
$16.73 (2.76%) $0.45

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
327%
 
S&P 500 Returns
105%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.